Sonia M. Uriona

Barcelona, CT 08035, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.

Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018.

Journal: Emerging infectious diseases

Published: April 21, 2022

Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.

Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.

Journal: Vaccines

Published: November 08, 2021

Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine.

Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine.

Journal: Anales de pediatria

Published: February 18, 2021

Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era.

Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era.

Journal: Epidemiology and infection

Published: November 05, 2020

Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study.

Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study.

Journal: Vaccines

Published: June 07, 2020

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain.

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain.

Journal: Emerging infectious diseases

Published: May 23, 2020

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: May 18, 2020

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: May 18, 2020

Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units

Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units

Journal: Anales de pediatria

Published: November 21, 2019

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era.

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era.

Journal: Pediatric pulmonology

Published: June 20, 2018

A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.

A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: April 05, 2018

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Journal: PloS one

Published: May 02, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026